Growth inhibition and sensitization to methotrexate plus zoledronic acid in osteosarcoma cells / 中国矫形外科杂志

ABSTRACT

[Objective] To explore the possible interest of therapeutic approaches including nitrogen-containing biphosphonate zoledronic acid using osteosarcoma cell lines MG63,and to investigate whether there is a synergism between zoledronic acid and methotrexate.[Method]Zoledronic acid alone or combined with methotrexate was used to treat human ostoesarcoma cells line MG63.The cell growth inhibition was assessed by MTT.[Result]There was a dose-dependent and time-dependent(1-100?mol/L)inhibition of cell proliferation by zoledronic acid.IC50 value of zoledronic acid for therapy of MG63 after 72h was 9.39 ?mol/L.The cell growth inhibition rates of MG63 at 72 h was 48.95% in zoledronic acid(10 ?mol/L)group,and 37.68%,45.93% and 52.42% in methotrexate groups MTX(1,10 and 100 mg/L).When combined treatment of zoledronic acid(10?mol/L)and methotrexate(1,10 and 100 mg/L)was used,the cell growth inhibition rates were 51.96%,66.77% and 69.23%,respectively.The combination of zoledronic acid and methotrexate demonstrated a synergistic effect.The differences were significant(P